Drew Weissman’s 2 children: Meet Rachel Weissman and Allison Weissman
American physician-scientist and 2023 Nobel Prize laureate Drew Weissman is a family man, who lives with his wife and children. He is a father of two adorable daughters.
Meet Drew Weissman’s two children Rachel Weissman and Allison Weissman
Their two cherished children, Rachel and Allison Weissman, are part of the close-knit family that Drew Weissman and his wife have been blessed with.
The couple planned the future of their daughters. Drew’s wife Mary Ellen told the Washington Post that they prioritised their daughter’s education and took them to good schools.
Rachel Weissman is the oldest child of the couple, and Allison Weissman is the youngest. They are adult now.
Drew Weissman and Katalin Karikó launched RNARx in 2006 with the goal of advancing RNA treatments.
In 2020, when their modified RNA technology was instrumental in the creation of the Pfizer/BioNTech and Moderna COVID-19 vaccines, they achieved a tremendous feat as a result of their commitment to advancing RNA technology.
A tremendous advancement in vaccine technology, these vaccines were quickly distributed throughout the world to prevent the COVID-19 epidemic.
Beyond COVID-19, Drew Weissman has bigger plans. He thinks that this method might be used to create vaccinations against other contagious illnesses like HIV, herpes, and influenza. Additionally, Weissman has worked closely with researchers at Chulalongkorn University in Thailand, actively assisting in the creation and distribution of COVID-19 vaccinations for Thailand and surrounding low-income nations that may encounter difficulties in the future.
Drew Weissman is regarded as a key expert in the field of immunology and medical research as a result of his groundbreaking work in RNA biology and vaccine production, which has not only gained him notoriety but also had a substantial impact on international efforts to fight infectious illnesses.
Weissman has contributed to the invention of various patents, such as US8278036B2 and US8748089B2, which were developed in collaboration with Katalin Karikó. These patents outline the necessary modifications to adapt RNA for applications in vaccines and other medical therapies.
Subsequently, Gary Dahl, the founder and CEO of Cellscript, obtained licenses for these patents and further extended the licenses to Moderna and BioNTech, allowing them to incorporate this technology into their COVID-19 vaccines.
